Swift Biosciences launches Amplicon technology

Single-Tube,MultiplexAmpliconSequencingforIllumina®platforms

Swift Biosciences, Inc. today announced the launch of an early access program for Accel-NGS™ Amplicon Panels for use with Illumina Next Generation Sequencing (NGS) systems. The assays are compatible with FFPE and circulating cell free DNA from 10 ng of genomic DNA. The underlying technology enables hundreds of primer pairs to be amplified in a single tube. The panels can be used to target either contiguous coverage of a single gene, multiple loci throughout the genome, or a combination of both.

The initial product is a comprehensive TP53 panel, a clinically important tumor suppressor gene.* This panel covers all coding exons of TP53 in a single tube format. Another panel under development based on this technology targets over 200 clinically relevant oncology mutations. Swift Biosciences will also soon offer custom panel design capability.

“We are excited about offering an early access program for translational researchers. Our multiplex amplicon panels achieve high performance metrics, such as percent on-target and coverage uniformity,” said David Olson, Chief Executive Officer at Swift Biosciences. “This new technology has a rapid workflow allowing identification of important mutations in a cost effective manner.”

Accel-NGS Amplicon Panels for Illumina add to the growing portfolio of products from Swift Biosciences. This new family of products joins the Accel-NGS 1S DNA and Accel-NGS 2S DNA Library Prep kits launched earlier in 2014.

The company has also developed qPCR reagents for mutation detection. The myT® Primer technology provides both high sensitivity and specificity in somatic mutation detection, making it ideal for cancer research and diagnostic applications. To date, Swift has developed myT Primer assays for common mutations in the BRAF and KRAS genes that offer best in class sensitivity.

* These products are for Research Use Only. Not for use in diagnostic procedures.